Drug Interaction Report
1 drug interaction and 4 additional warnings found for the following 2 drugs:
- pemigatinib
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:pemigatinib trofinetide
Applies to: pemigatinib, trofinetide
Trofinetide may increase the blood levels and effects of pemigatinib.
Talk to your doctor if you have any questions or concerns.
You may need more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle pemigatinib
Applies to: pemigatinib
Pemigatinib may be taken with or without food.
Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with pemigatinib unless directed otherwise by your doctor.
Grapefruit juice can increase the blood levels of pemigatinib. This may increase the frequency and severity of serious side effects such as:
- elevated phosphate levels in the blood (which can eventually lead to low blood calcium levels; calcium deposits in the skin, muscles, and other tissues; anemia; muscle cramps; seizures; and irregular heart rhythm)
- eye and vision problems
- joint pain
- mouth sores and inflammation
- hair loss
- diarrhea
- nausea
- vomiting
- constipation
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
3 potential interactionsApplies to: 3 conditions, including Liver Disease, Visual Defect/Disturbance, and Renal Dysfunction.
Liver Disease
Moderate:pemigatinib
Pemigatinib has a moderate potential interaction with Liver Disease.
The recommended dosage of pemigatinib should be reduced in patients with severe hepatic dysfunction. No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Renal Dysfunction
Moderate:pemigatinib
Pemigatinib has a moderate potential interaction with Renal Dysfunction.
The recommended dosage of pemigatinib should be reduced in patients with severe renal disease. No dose adjustment is recommended for patients with mild or moderate renal impairment, or those patients with end-stage renal disease receiving intermittent hemodialysis.
Visual Defect/Disturbance
Moderate:pemigatinib
Pemigatinib has a moderate potential interaction with Visual Defect/Disturbance.
Pemigatinib can cause retinal pigment epithelial detachment (RPED), which may cause symptoms such as blurred vision, visual floaters, or photopsia. A comprehensive ophthalmological examination including an optical coherence tomography should be performed prior to treatment initiation. Patients with visual disturbances should be closely monitored.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.